Abstract
Previous cross-sectional studies indicated that low relative skeletal muscle mass against body weight (appendicular lean mass divided by body weight, ALM/Wt or divided by body mass index, ALM/BMI) was negatively associated with metabolic syndrome (MetS). The aim of this longitudinal study was to investigate the impact of low relative skeletal muscle mass and leg muscle power on the development of MetS in Japanese women in a 7-y prospective study. Subjects were 346 Japanese women aged 26 to 85 years. The reference values for Class I sarcopenia were defined as values one SD below the sex-specific means of the young group. The longitudinal relation between muscle mass or leg power and development of MetS was examined using Kaplan-Meier curves and Cox regression models (average follow-up duration 7 years, range 1 to 10 years). During follow-up, 24 of subjects developed MetS. Both indices of ALM/Wt or ALM/BMI, the incidence of MetS was higher in Class I sarcopenia group than normal muscle mass group even after controlling variables (adjusted hazard ratio [AHR] = 3.22 [95%CI; 1.25-8.27] for ALM/Wt and 3.19 [95%CI; 1.31-7.74] for ALM/BMI). In contrast, for the leg power per body weight, the incidence of MetS was not significantly different between low leg power and normal leg power groups (AHR = 1.23 [95%CI; 0.50-3.04]). Current longitudinal study indicated that low relative skeletal muscle mass but not low leg power was independent risk factors for the development of MetS in Japanese women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures were reviewed and approved by the ethics committees of the National Institutes of Biomedical Innovation, Health and Nutrition (6008, Kenei14-02). All participants provided written consent for participation in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
hnanri{at}nibiohn.go.jp, takashi.nakagata{at}gmail.com, d2watanabe{at}nibiohn.go.jp, t-yoshida{at}nibiohn.go.jp, yhatamoto{at}nibiohn.go.jp, eyoshi{at}nibiohn.go.jp
haruka-m{at}fc.ritsumei.ac.jp, ksanada{at}fc.ritsumei.ac.jp
r.kawakami{at}aoni.waseda.jp, miyachim{at}waseda.jp
gando.yuko{at}surugadai.ac.jp
miyatake.nobuyuki{at}kagawa-u.ac.jp
Data Availability
Data cannot be shared publicly because of Guideline of the Ethics Committee